STOCK TITAN

BCYC insider files Form 144 to sell 102 shares on Nasdaq

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Bicycle Therapeutics plc (BCYC) filed a Form 144 notice reporting a proposed sale of 102 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $872, intended for sale on 10/02/2025 on Nasdaq. The filing discloses that 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and were paid as equity compensation. The form also reports that the filer sold 411 shares on 07/02/2025 for gross proceeds of $3,058. The notice includes the statutory representation that the seller does not possess undisclosed material adverse information about the issuer.

Positive

  • Form 144 was filed, disclosing the proposed sale of 102 shares
  • Broker named: Stifel Nicolaus & Company Inc
  • Acquisition of 218 shares on 10/02/2025 was via Restricted Stock Units and paid as equity compensation
  • Previous sale disclosed: 411 shares sold on 07/02/2025 for $3,058

Negative

  • None.

Insights

Form 144 filed to report an insider's proposed sale of 102 shares for $872 on 10/02/2025.

The filing identifies the broker as Stifel Nicolaus & Company Inc and specifies the market where the shares will be sold: Nasdaq. It also documents the acquisition of 218 shares on 10/02/2025 as Restricted Stock Units paid via equity compensation.

The form lists a prior disposition of 411 shares on 07/02/2025 producing $3,058 in gross proceeds. This information is procedural disclosure required under Rule 144 and confirms compliance steps for an insider sale; no additional material facts or regulatory actions are disclosed in the filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Bicycle Therapeutics' (BCYC) Form 144 report?

The form reports a proposed sale of 102 shares of common stock through Stifel Nicolaus with an aggregate market value of $872, to be sold on 10/02/2025 on Nasdaq.

How were the securities that may be sold acquired?

The filing states 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and paid as equity compensation.

Did the filer sell any BCYC shares recently?

Yes. The filing discloses a prior sale of 411 shares on 07/02/2025 that generated $3,058 in gross proceeds.

Which broker will handle the proposed sale?

The proposed sale lists Stifel Nicolaus & Company Inc as the broker.

On which exchange is the sale intended to occur?

The form specifies the sale is intended to occur on Nasdaq.
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

484.88M
49.14M
1.4%
88.35%
2.29%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE